Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >API >Synthetic Anti-infective Drugs >Favipiravir

Favipiravir

Favipiravir Structure
  • ₹0
  • Product name: Favipiravir
  • CAS: 259793-96-9
  • MF: C5H4FN3O2
  • MW: 157.1
  • EINECS:1533716-785-6
  • MDL Number:MFCD12032148
  • Synonyms:Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo- (9CI);Favipiravir;Unii-ew5gl2X7E0;6-fluoro-3,4-dihydro-3-oxo- (9CI);PYRAZINECARBOXAMIDE, 6-FLUORO-3,4-DIHYDRO-3-OXO-;2-PyrazinecarboxaMide, 6-fluoro-3,4-dihydro-3-oxo-;6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxaMide;PyrazinecarboxaMide, 6-fl...
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Melting point :>151°C (dec.)
Density :1.78±0.1 g/cm3(Predicted)
storage temp. :under inert gas (nitrogen or Argon) at 2-8°C
solubility :Soluble in DMSO (30 mg/mL), water (12 mg/mL with warming)
form :solid
pka :8.77±0.60(Predicted)
color :Off-white
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO or water may be stored at -20° for up to 3 months.

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H341 Suspected of causing genetic defects Germ cell mutagenicity Category 2 Warning P201,P202, P281, P308+P313, P405,P501
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P405 Store locked up.
P501 Dispose of contents/container to..…

Description

Favipiravir is a new broad-spectrum antiviral drug targeting RNA-dependent RNA polymerase (RdRp) developed by Japan's Toyama Chemical Pharmaceutical Company. It was approved for marketing in Japan in March 2014 for the treatment of new and recurrent influenza. During the outbreak of the new coronavirus, the results of the Phase I clinical study of the drug published in March 2020 showed that the drug may have the effect of speeding up virus clearance to alleviate the progress of new coronavirus pneumonia.

Related product price